Recent deals include the completed acquisition of efimosfermin, a potential treatment for liver disease, and new partnerships with Hengrui Pharma, aimed at developing up to 12 medicines in ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

Driven by exceptional growth in Specialty Medicines and Vaccines, GSK’s second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding ...

Elsewhere in the MASH space, GSK in May bet $2 billion to acquire Boston Pharmaceuticals’ efimosfermin alfa, an investigational FGF21 analog that works by helping to lower fat, easing inflammation and ...

Madrigal does have one notable challenger on its horizon, with GSK poised to enter the MASH arena in the next few years after it bought Boston Pharmaceuticals’ Phase III-ready efimosfermin alfa, an ...

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ALT stock is downgraded to hold.